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It is nought good a slepyng hound to wake.
Troilus and Criseyde (1380), Chaucer
In the previous issue of Breast Cancer Research, Karimi-
Busheri and colleagues [1] shed further light on the rela-
tive resistance in breast cancer-derived tumor-initiating 
cells (TICs) by interrogating DNA damage signaling and 
repair and the capacity for tumor cell senescence in 
CD24−/low/CD44+ cells derived from MCF-7 mammo-
spheres. Primary or adjuvant breast radiotherapy is an 
important component in multimodality therapy as a 
means to improve locoregional control and potentially 
improve overall survival [2,3]. Understanding the biology 
underlying the relative radiosensitivity of breast tumor 
clonogens is an important step in personalized medicine 
to eﬀ  ectively predict clinical response and develop novel 
targeted therapies.
In this context, Karimi-Busheri and colleagues [1] add 
to the increasing literature using established cell lines 
and primary tumor explants on TIC resistance as the 
basis of treatment failure following radiotherapy and 
chemo  therapy treatments [4-9]. Like previous investi-
gators, the authors show that when compared with non-
TIC monolayer cultures, TIC mammo  sphere clonogens 
have a decreased production of reactive oxygen species 
following ionizing radiation (IR) [7] and bypass the ATM/
DNA-PKcs-dependent phos  phory  lation of the histone 
H2AX in response to IR-induced DNA double-strand 
breaks (DSBs) [5]. Despite the bypass of the γH2AX 
response, TICs acquire hyper  phosphorylation of down-
stream signaling proteins such as p53, RB, and CHK2, a 
ﬁ  nding initially reported in glioma TIC studies [10].
As other investigators have reported, activation of AKT 
and canonical WNT signaling pathways within breast 
cancer TIC subpopulations has resulted in increased 
eﬃ   ciency of DNA repair [5,6]. However, an increased 
capacity for DSB repair is not a universal ﬁ  nding in all 
TIC subpopulations [11] and may be dependent on the 
cell model, culture conditions, and diﬀ  erent DSB assays. 
When a number of assays were used, DSB repair in TICs 
was unaﬀ   ected in the study by Karimi-Busheri and 
colleagues [1]. However, the authors observed an increased 
capacity for the repair of DNA single-strand breaks 
(SSBs) associated with an increased expression of the 
APE1 protein. However, we do not know whether this is 
Abstract
Preclinical data from cell lines and experimental tumors 
support the concept that breast cancer-derived tumor-
initiating cells (TICs) are relatively resistant to ionizing 
radiation and chemotherapy. This could be a major 
determinant of tumor recurrence following treatment. 
Increased clonogenic survival is observed in CD24−/low/
CD44+ TICs derived from mammosphere cultures and 
is associated with (a) reduced production of reactive 
oxygen species, (b) attenuated activation of γH2AX 
and CHK2-p53 DNA damage signaling pathways, 
(c) reduced propensity for ionizing radiation-induced 
apoptosis, and (d) altered DNA double-strand or DNA 
single-strand break repair. However, recent data have 
shed further light on TIC radioresistance as irradiated 
TICs are resistant to tumor cell senescence following 
DNA damage. Taken together, the cumulative data 
support a model in which DNA damage signaling 
and repair pathways are altered in TICs and lead to an 
altered mode of cell death with unique consequences 
for long-term clonogen survival. The study of TIC 
senescence lays the foundation for future experiments 
in isogenic models designed to directly test the 
capacity for senescence and local control (that is, not 
solely local regression) and spontaneous metastases 
following treatment in vivo. The study also supports 
the targeting of tumor cell senescence pathways to 
increase TIC clonogen kill if the targeting also maintains 
the therapeutic ratio.
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Where the authors truly advance the ﬁ  eld is in their 
mechanistic studies of the mode of cell death in irradiated 
TICs versus non-TICs. Although breast cancer TICs can 
express high levels of antiapoptotic proteins, such as 
survivin or the BAX/BCL-2 family [9], the authors did not 
observe TIC resistance to IR-induced apoptosis. Instead, 
they observed that irradiated TICs have reduced tumor 
cell senescence associated with increased telomerase 
activity and increased expression of the senescence-asso-
ciated proteins, including ING1, p21WAF, and SA-β 
galacto sidase.  Th  ese results echo recent data in which 
fractionated IR led to a relative increase in the fraction of 
senescent cells in vitro in breast cancer non-TICs versus 
TICs [12]. Th  e reader is left wondering how DSB repair 
can be normal in TICs when the ATMser1981, γH2AX, 
p53Ser15, and pRB responses are abnormal. Future experi-
ments therefore are required to study the upstream activa-
tion of the MRE11-RAD50-NBS1 (MRN) complexes, altered 
chro  ma  tin states in TICs before and after IR, and the rela-
tive control and activation of telomerase activity in TICs 
[5]. Nonetheless, the cumulative data support a model in 
which DNA damage signaling and repair pathways are 
altered in TICs and lead to altered modes of cell death with 
unique consequences for long-term clonogen survival [13].
Figure 1. Model of tumor cell senescence in breast cancer tumor-initiating cells (TICs) as a determinant of radiocurability. The failure 
of ionizing radiation to initiate tumor cell senescence in CD24−/low/CD44+ MCF-7 TICs (derived from mammosphere culture) leads to relative 
radioresistance over non-TIC monolayer cells (TIC = red circle; non-TIC = blue circle). Resistant TICs have attenuated or abnormal reactive oxygen 
species (ROS) production, abnormal DNA damage signaling and checkpoint control, and an altered propensity for ionizing radiation-induced tumor 
cell senescence. The number and sensitivity of TIC populations could vary from patient to patient and refl  ect individual patient radiocurability 
within clinical cohorts. On the left are examples of patient-specifi  c scenarios in which the initial fraction of TICs is varied prior to potentially curative 
fractionated radiotherapy. On the right are scenarios that represent radiotherapy cure or failure. Sterilizing all TIC clonogens and killing non-TICs 
via tumor cell senescence in patient 1 lead to both tumor regression and local control (for example, tumor cure). The failure to activate tumor 
senescence and kill any TIC or non-TIC leads to a complete lack of response and local failure in patient 3. Patient 2 shows a mixed response in 
which non-TIC populations are killed, leading to initial tumor regression, but owing to the re-growth of TIC clonogens, the patient ultimately fails 
therapy. Future research will require exquisite biomarkers to delineate the fraction of TICs within pretreatment tumor biopsies as means to predict 
radiotherapy response in the context of personalized medicine. Concepts shown are based on the work of Karimi-Busheri and colleagues [1]. DSB, 
DNA double-strand break; SSB, DNA single-strand break.
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directly to the relative radiocurability or chemosensitivity 
in vivo among individual patients in the clinic is not 
straightforward. If TICs are relatively resistant and 
determine the overall curability of a given tumor, to what 
extent do TIC number and radiosensitivity vary from 
patient to patient? Does this explain why one patient is 
cured and another has an initial regression only to 
undergo subsequent local or systemic recurrence 
(Figure  1)? From quantitative preclinical studies using 
syngeneic murine tumors or human xenografts, we know 
that the proportion and radiosensitivity of TICs can be 
measured and reﬂ  ect radiocurability in vivo [14,15]. Yet 
this relationship may be further complicated by intra-
tumor heterogeneity in which hypoxia subregions can 
provide a niche for TIC survival, aggressiveness, and 
increased metastatic capacity [16,17]. Indeed, it is still 
unclear whether local radioresistance equates directly 
with an increased capacity for systemic metastases 
[18,19]. At present, one cannot translate a diﬀ  erential 
capacity for DNA damage response and tumor cell 
senescence in TICs to a globally resistant tumor cell 
phenotype. But the data on TIC senescence lay the 
foundation for future experiments in isogenic models 
designed to directly test the capacity for senescence and 
local control (that is, not solely local regression) and 
spontaneous metastases following treatment in vivo [13].
Th  e hope for personalized medicine is predicated on 
understanding the unique biology within and between 
tumors and applying this knowledge to oﬀ  er the best 
treatment using radiotherapy, chemotherapy, or novel 
molecular-targeted agents [20]. Drilling down into the 
biology of rare TIC populations within clinical biopsies 
or tissues derived from solid tumors requires a level of 
sophistication that is currently lacking for the develop-
ment and validation of single-cell TIC senescence bio-
markers  in vivo [9]. However, targeting tumor cell 
senescence pathways could increase TIC clonogen kill if 
this approach maintains the therapeutic ratio whereby 
cell kill in tumors is increased when compared with cell 
kill in normal tissues [9,13,21]. Such a strategy would 
drive the therapeutic concept of ‘let sleeping dogs lie’ or, 
in this case, ‘die’.
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